Plasminogen activator inhibitor 1. Structure of the native serpin, comparison to its other conformers and implications for serpin inactivation

Journal of Molecular Biology

Volumn 297, Issue 3, 2000, Pages 683-695

  Nar, Herbert ^a   Bauer, Margit ^a   Stassen, Jean Marie ^a   Lang, Dietmar ^b   Gils, Ann ^c   Declerck, Paul J ^c  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b EUROPEAN MOLECULAR BIOLOGY LABORATORY   (Germany)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

PAI 1; Plasminogen activator inhibitor; Serpin; TPA, crystal structure

Indexed keywords

DIMER; ISOPROTEIN; MUTANT PROTEIN; PLASMINOGEN ACTIVATOR INHIBITOR 1; VITRONECTIN;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; PROTEIN DOMAIN; PROTEIN QUATERNARY STRUCTURE; PROTEIN SECONDARY STRUCTURE; PROTEINASE INHIBITION; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

EID: 0034737309     PISSN: 00222836     EISSN: None     Source Type: Journal    
DOI: 10.1006/jmbi.2000.3604     Document Type: Article

References (61)

1. Mechanisms contributing to the conformational and functional flexibility of plasminogen activator inhibitor-1
2. Purification and characterization of natural and recombinant human plasminogen activator inhibitor-1 (PAI-1)
3. Plasminogen activator inhibitor type-1: Reactive centre and amino-terminal heterogeneity determined by protein and cDNA sequencing
4. Molecular evolution of plasminogen activator inhibitor 1 functional stability
5. Identification of the binding site for a low molecular weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis
6. Natural protein proteinase inhibitors and their interaction with proteinases
7. The free R-value: A novel statistical quantity for assessing the accuracy of crystal structures
8. The biostructural pathology of the serpins: Critical function of sheet opening mechanism
9. Biological implications of a 3 A structure of dimeric antithrombin
10. The CCP4 suite: Programs for protein crystallography
11. Purification and characterization of a plasminogen activator inhibitor 1 binding protein from human plasma. Identification as a multimeric form of S protein (vitronectin)
12. Identification of a conformationally distinct form of plasminogen activator inhibitor-1, acting as a noninhibitory substrate for tissue-type plasminogen activator
13. Inhibitory conformation of the reactive loop of alpha 1-antitrypsin
14. Divining the serpin inhibition mechanism: A suicide substrate springe?
15. Structure-function relationships in serpins: Current concepts and controversies
16. Substrate behaviour of plasminogen activator inhibitor-1 is not associated with a lack of insertion of the reactive site loop
17. cDNA cloning of human plasminogen activator-inhibitor from endothelial cells
18. Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants
19. Implications of the three-dimensional structure of α1-antitrypsin for the structure and function of serpins
20. A 2.6 Å structure of a serpin polymer and implications for conformational disease
21. Protein inhibitors of proteinases
22. Purification of active human plasminogen activator inhibitor 1 from Escherichia coli. Comparison with natural and recombinant forms purified from eucaryotic cells
23. Localisation of vibronectin binding domain in plasminogen activator inhibitor-1
24. Serpin reactive centre loop mobility is required for inhibitor function but not for enzyme recognition
25. Characterization of the binding of different conformational forms of plasminogen activator inhibitor-1 to vitronectin
26. The mechanism of the reaction between human plasminogen-activator inhibitor 1 and tissue plasminogen activator
27. Human alpha-1-proteinase inhibitor: Crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function
28. Preparation and characterization of latent α1-antitrypsin
29. Regulation of cell adhesion by PAI-1
30. Solvent content of protein crystals
31. cDNA for bovine type 1 plasminogen activator inhibitor (PAI-1)
32. Structural basis of latency in plasminogen activator inhibitor-1
33. Interconversions between active, inert and substrate forms of denatured/refolded type-1 plasminogen activator inhibitor
34. AMoRe: An automated package for molecular replacement
35. Cloning and sequence of a cDNA coding for the human beta-migrating endothelial-cell-type plasminogen activator inhibitor
36. Endothelial plasminogen activator inhibitor (PAI): A new member of the serpin gene family
37. Conformational studies on plasminogen activator inhibitor (PAI- 1) in active, latent, substrate, and cleaved forms
38. On the size of the active site in proteases
39. The intact and cleaved human antithrombin III complex as a model for serpin-proteinase interactions
40. A spectroscopic study of the structures of latent, active and reactive centre cleaved type 1 plasminogen activator inhibitor
41. The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesion
42. Crystal structure of an uncleaved alpha 1-antitrypsin reveals the conformation of its inhibitory reactive loop
43. The latent tendencies of PAI-1
44. Serpin tertiary structure transformation
45. Engineering of plasminogen activator inhibitor-1 to reduce the rate of latency transition
46. A substrate-like form of plasminogen-activator-inhibitor type 1. Conversions between different forms by sodium dodecyl sulphate
47. Dynamic structural and functional relationships in recombinant plasminogen activator inhibitor-1 (rPAI-1)
48. Evaluation of the mechanism of inactivation of plasminogen activator inhibitor-1 by monoclonal antibodies using a stable variant
49. Crystal structure of an uncleaved serpin reveals the conformation of an inhibitory reactive loop
50. The inhibition mechanism of serpins
51. Plasminogen activator inhibitor 1 (PAI-1) in its active conformation: Crystallization and preliminary X-ray diffraction data
52. Induction of conformational changes within crystals of plasminogen activator inhibitor-1 (PAI-1)
53. Plasminogen activator inhibitor 1 (PAI-1) in plasma: Its role in thrombotic disease
54. Predictive value of fibrinolytic factors in coronary heart disease
55. Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasma
56. Crystal structure of plakalbumin, a proteolytically nicked form of albumin. Its relationship to the structure of cleaved alpha-1-proteinase inhibitor
57. Interfering with the inhibitory mechanism of serpins: Crystal structure of a complex formed between cleaved plasminogen activator inhibitor type 1 and a reactive centre loop peptide
58. Detecting and overcoming crystal twinning